Literature DB >> 29516879

Patients at high risk of tuberculosis recurrence.

Mehdi Mirsaeidi1, Ruxana T Sadikot2.   

Abstract

Recurrent tuberculosis (TB) continues to be a significant problem and is an important indicator of the effectiveness of TB control. Recurrence can occur by relapse or exogenous reinfection. Recurrence of TB is still a major problem in high-burden countries, where there is lack of resources and no special attention is being given to this issue. The rate of recurrence is highly variable and has been estimated to range from 4.9% to 47%. This variability is related to differences in regional epidemiology of recurrence and differences in the definitions used by the TB control programs. In addition to treatment failure from noncompliance, there are several key host factors that are associated with high rates of recurrence. The widely recognized host factors independent of treatment program that predispose to TB recurrence include gender differences, malnutrition; comorbidities such as diabetes, renal failure, and systemic diseases, especially immunosuppressive states such as human immunodeficiency virus; substance abuse; and environmental exposures such as silicosis. With improved understanding of the human genome, proteome, and metabolome, additional host-specific factors that predispose to recurrence are being identified. Information on temporal and geographical trends of TB cases as well as studies with whole-genome sequencing might provide further information to enable us to fully understand TB recurrence and discriminate between reactivation and new infection. The recently launched World Health Organization End TB Strategy emphasizes the importance of integrated, patient-centered TB care. Continued improvement in diagnosis, treatment approaches, and an understanding of host-specific factors are needed to fully understand the clinical epidemiological and social determinants of TB recurrence.

Entities:  

Keywords:  Recurrence; risk factors; tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 29516879     DOI: 10.4103/ijmy.ijmy_164_17

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  17 in total

1.  Specific urban units identified in tuberculosis epidemic using a geographical detector in Guangzhou, China.

Authors:  Hongyan Ren; Weili Lu; Xueqiu Li; Hongcheng Shen
Journal:  Infect Dis Poverty       Date:  2022-04-15       Impact factor: 10.485

Review 2.  Molecular Dynamic Simulations and Molecular Docking as a Potential Way for Designed New Inhibitor Drug without Resistance.

Authors:  Jafar Aghajani; Poopak Farnia; Parissa Farnia; Jalaledin Ghanavi; Ali Akbar Velayati
Journal:  Tanaffos       Date:  2022-01

3.  The prevalence and risks of major comorbidities among inpatients with pulmonary tuberculosis in China from a gender and age perspective: a large-scale multicenter observational study.

Authors:  Wanli Kang; Jian Du; Song Yang; Jiajia Yu; Hongyan Chen; Jianxiong Liu; Jinshan Ma; Mingwu Li; Jingmin Qin; Wei Shu; Peilan Zong; Yi Zhang; Yongkang Dong; Zhiyi Yang; Zaoxian Mei; Qunyi Deng; Pu Wang; Wenge Han; Meiying Wu; Ling Chen; Xinguo Zhao; Lei Tan; Fujian Li; Chao Zheng; Hongwei Liu; Xinjie Li; A Ertai; Yingrong Du; Fenglin Liu; Wenyu Cui; Quanhong Wang; Xiaohong Chen; Junfeng Han; Qingyao Xie; Yanmei Feng; Wenyu Liu; Peijun Tang; Jianyong Zhang; Jian Zheng; Dawei Chen; Xiangyang Yao; Tong Ren; Yang Li; Yuanyuan Li; Lei Wu; Qiang Song; Mei Yang; Jian Zhang; Yuanyuan Liu; Shuliang Guo; Kun Yan; Xinghua Shen; Dan Lei; Yangli Zhang; Xiaofeng Yan; Liang Li; Shenjie Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-22       Impact factor: 3.267

4.  Effect of high glucose on cytokine production by human peripheral blood immune cells and type I interferon signaling in monocytes: Implications for the role of hyperglycemia in the diabetes inflammatory process and host defense against infection.

Authors:  Ronghua Hu; Chang-Qing Xia; Edward Butfiloski; Michael Clare-Salzler
Journal:  Clin Immunol       Date:  2018-06-09       Impact factor: 3.969

Review 5.  Advancing our understanding of HIV co-infections and neurological disease using the humanized mouse.

Authors:  Janice J Endsley; Matthew B Huante; Kubra F Naqvi; Benjamin B Gelman; Mark A Endsley
Journal:  Retrovirology       Date:  2021-06-16       Impact factor: 4.602

6.  Tuberculosis Specific Interferon-Gamma Production in a Current Refugee Cohort in Western Europe.

Authors:  Alexandra Jablonka; Christian Dopfer; Christine Happle; Georgios Sogkas; Diana Ernst; Faranaz Atschekzei; Stefanie Hirsch; Annabelle Schäll; Adan Jirmo; Philipp Solbach; Reinhold Ernst Schmidt; Georg M N Behrens; Martin Wetzke
Journal:  Int J Environ Res Public Health       Date:  2018-06-14       Impact factor: 3.390

7.  Classifying recurrent Mycobacterium tuberculosis cases in Georgia using MIRU-VNTR typing.

Authors:  Nino Maghradze; Levan Jugheli; Sonia Borrell; Nestani Tukvadze; Rusudan Aspindzelashvili; Zaza Avaliani; Klaus Reither; Sebastien Gagneux
Journal:  PLoS One       Date:  2019-10-18       Impact factor: 3.240

8.  Small Animal Model of Post-chemotherapy Tuberculosis Relapse in the Setting of HIV Co-infection.

Authors:  Matthew B Huante; Tais B Saito; Rebecca J Nusbaum; Kubra F Naqvi; Sadhana Chauhan; Robert L Hunter; Jeffrey K Actor; Jai S Rudra; Mark A Endsley; Joshua G Lisinicchia; Benjamin B Gelman; Janice J Endsley
Journal:  Front Cell Infect Microbiol       Date:  2020-04-16       Impact factor: 5.293

9.  Proteomic analysis of infected primary human leucocytes revealed PSTK as potential treatment-monitoring marker for active and latent tuberculosis.

Authors:  Benjawan Kaewseekhao; Sittiruk Roytrakul; Yodying Yingchutrakul; Kanin Salao; Wipa Reechaipichitkul; Kiatichai Faksri
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

10.  Recurrent Tuberculosis Disease in Singapore.

Authors:  Suay Hong Gan; Kyi Win KhinMar; Li Wei Ang; Leo K Y Lim; Li Hwei Sng; Yee Tang Wang; Cynthia B E Chee
Journal:  Open Forum Infect Dis       Date:  2021-06-27       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.